explore -WSS

explore

author：entertainment 2025-10-02 17:22:26 - browse：61

Truvian Health employee with a plate holding reagents used to measure commonly tested blood markers. Truvian

SAN DIEGO — Truvian Health, a San Diego blood diagnostics company, shared data on Tuesday showing that its benchtop instrument’s results are largely consistent with those generated by large central laboratories. But while the results lend support for the company’s vision of decentralized and widely available clinical testing, they also resurface questions about the value of an approach widely associated with the now defunct and notorious Bay Area startup Theranos.

In a multisite study, the company tested nearly 240 blood samples from healthy donors and chronic disease patients for dozens of blood-based measurements commonly ordered by doctors, from cholesterol to blood sugar to blood cell counts. Results from Truvian’s benchtop analytical instrument, with few exceptions, closely matched readings from devices used in large central labs and made by Swiss pharma giant Roche and Japanese firm Sysmex.

The findings were presented at the annual meeting of the American Association for Clinical Chemistry, recently rebranded as the Association for Diagnostics & Laboratory Medicine. It’s the first time Truvian has shared clinical data on its product, though they have not been published in a peer-reviewed journal. The company, which is planning additional validation studies, expects to submit for Food and Drug Administration approval of its device by the third quarter of 2024.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Moonlake's readout produced a cash windfall. Risks remain

hotspot

leisure time

WSS

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Medicare’s new pay boost for primary care is angering specialists

FDA reorg will put new emphasis on investigations, sources say

As demand for Covid shots wanes, Moderna seeks its next success

Apple is now the first public company to be valued at $3 trillion

Wildfire smoke exposes gaps in outdoor worker protections

focus

explore

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

BioMarin wins approval for gene therapy to treat hemophilia A

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cancer drug shortages should be causing more outrage

BioMarin wins approval for gene therapy to treat hemophilia A

Publishing genetic code of viruses could cause disaster

After affirmative action ruling, medical educators look to 'holistic review'

Medical leaders decry Supreme Court decision on affirmative action

Medicare details structure of new drug price negotiation program

What is STAT's opinion section for?

hotspot

Ohio still needs to do more to protect the right to abortion

Today's health inequities arise from racist U.S. history, say experts

After affirmative action ruling, medical educators look to 'holistic review'

Jerome Adams on the need for new antivirals for Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Carbon Health diabetes program, a test of data

focus

hotspot

leisure time

hotspot